Rare Disease Disorders And CNS Drug Development – Paving The Way For Precision Medicine
In CNS drug development, more and more diseases once viewed as common are now known to be collections of rare variants. Our deepening understanding of the human genome and pathophysiology has led to fragmented classifications of common neurological or psychiatric disorders based on identified genetic markers. This trend of replacing larger classifications of common disorders with a more precisely defined spectrum of individual rare and ultra-rare diseases is changing the face of clinical research and development, not only in CNS but across virtually all therapeutic areas. What were once syndromes are now collections of diseases with common expression. Rare diseases are showing the way toward precision medicine for common disorders. Join medical experts from Medpace’s neuroscience team as they explore this shifting clinical development landscape.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.